Human immunoglobulin G4 Fc fragment (h-CH2-CH3-CHS domains [Homo sapiens IGHG4*01 (hinge (1-4), CH2 (5-114), CH3 (115-219), CHS (220-221))]) (1-221), disulfide bridged dimer, produced in Escherichia coli, with one Fc chain conjugated (P <sup>1</sup> ?C<sup>30''</sup>) via a bifunctional maleimide-polyethylene glycol-aldehyde linker to a synthetic glucagon peptide analogue (1''-30'') E<sup>16’'<sup> ?K <sup>20'' <sup>linked by a lactam ring)
Overweight With Comorbidities
Hanmi Pharmaceutical Company Limitedprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
575 Active assets in the Overweight With Comorbidities cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
vi-0521 VIVUS LLC | Phase 4 | BBB |
Tirzepatide LABORATORIOS INDUFAR | Phase 4 | BBB |
Efsubaglutide Alfa The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 4 | BBB |
Phentermine Russell McCulloh, MD | Phase 4 | BBB |
Deoxycholic Acid University of California, San Diego | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Human immunoglobulin G4 Fc fragment (h-CH2-CH3-CHS domains [Homo sapiens IGHG4*01 (hinge (1-4), CH2 (5-114), CH3 (115-219), CHS (220-221))]) (1-221), disulfide bridged dimer, produced in Escherichia coli, with one Fc chain conjugated (P <sup>1</sup> ?C<sup>30''</sup>) via a bifunctional maleimide-polyethylene glycol-aldehyde linker to a synthetic glucagon peptide analogue (1''-30'') E<sup>16’'<sup> ?K <sup>20'' <sup>linked by a lactam ring) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →